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AbstrAct:
The Facilitates Chromatin Transcription (FACT) chromatin remodeling complex, 
comprised  of  two  subunits,  SSRP1  and  SPT16,  is  involved  in  transcription, 
replication and DNA repair. We recently showed that curaxins, small molecules 
with anti-cancer activity, target FACT and kill tumor cells in a FACT-dependent 
manner. We also found that FACT is overexpressed in human and mouse tumors 
and that tumor cells are sensitive to FACT downregulation. To clarify the clinical 
potential of FACT inhibition, we were interested in physiological role(s) of FACT 
in multicellular organisms. We analyzed SSRP1 and SPT16 expression in different 
cells, tissues and conditions using Immunohistochemical (IHC) staining of mouse 
and human tissues and analysis of publically available high-content gene expression 
datasets. Both approaches demonstrated coordinated expression of the two FACT 
subunits, which was primarily associated with the stage of cellular differentiation. 
Most cells of adult tissues do not have detectable protein level of FACT. High 
FACT expression was associated with stem or less-differentiated cells, while low 
FACT levels were seen in more differentiated cells. Experimental manipulation 
of cell differentiation and proliferation in vitro, as well as tissue staining for 
the  Ki67  proliferation  marker,  showed  that  FACT  expression  is  related  more  to 
differentiation than to proliferation. Thus, FACT may be part of a stem cell-like gene 
expression signature and play a role in maintaining cells in an undifferentiated 
state, which is consistent with its potential role as an anti-cancer target.
IntroductIon
FACT (Facilitates Chromatin Transcription) is 
a chromatin remodeling complex composed of two 
subunits,  Structure  Specific  Recognition  Protein  1 
(SSRP1)  and  Suppressor  of  Ty  16  (SPT16).  We  have 
identified FACT as a molecular target of a novel class of 
candidate anti-cancer agents named curaxins [1]. Curaxin-
induced “trapping” of FACT within chromatin alters 
FACT’s functions in tumor cells, resulting in activation 
of the pro-apoptotic p53 pathway, suppression of the anti-
apoptotic NF-κB pathway, and FACT-dependent tumor 
cell  death  [1].  We  also  found  that  expression  of  both 
FACT subunits was elevated in several types of mouse 
and human tumor cell lines as compared to their normal 
counterparts and that genetic knockdown of either FACT 
subunit compromised tumor cell viability [1]. These data 
suggest  that  FACT  might  play  a  role  in  development, 
maintenance or progression of cancer and, therefore, be 
a potential target for anti-cancer therapy via curaxins or 
other agents. However, an improved understanding of the 
physiological role(s) of FACT under normal conditions as 
well as its pattern of expression in mammals is necessary 
before the consequences of global FACT inhibition can 
be predicted and development of anti-FACT therapeutic 
approaches can proceed. 
There are indications in the literature that FACT 
may  be  expressed  at  constantly  high  levels  in  a Oncotarget 2 www.impactjournals.com/oncotarget
“housekeeping” fashion, similar to basic transcription 
factors.  For  example,  yeast  growth  was  prevented  by 
inactivating  mutations  in  either  FACT  subunit  [2-4], 
knockdown of the SSRP1 subunit of FACT in mice caused 
death on day E3.5 at the blastocyst stage [5], and SSRP1 
was also shown to be essential for Arabidopsis viability 
[6].  In  addition,  the  model  systems  used  to  study  the 
biochemical  function  of  FACT  in  mammals  (primarily 
HeLa cells) and yeast typically have very high levels of 
FACT expression. However, a limited number of other 
studies have shown that expression of at least SSRP1 is 
not ubiquitous among tissues of higher eukaryotes. First, 
it was shown that only highly proliferative mouse tissues 
express  detectable  SSRP1  RNA  and  protein    and  that 
SSRP1 levels decline upon induction of differentiation in 
vitro [7]. Second, indirect immunofluorescence analyses 
revealed co-localization of both FACT subunits in nuclei 
of  the  majority  of  cell  types  in  Arabidopsis thaliana 
embryos, shoots, and roots, while FACT was not present in 
terminally differentiated cells such as mature trichoblasts 
and cells of the root cap [8]. 
Although  FACT  is  involved  in  transcription  not 
all  types  of  transcription  depend  on  FACT.  In  human 
tumor cells knockdown of both FACT subunits changed 
expression  of  less  than  200  genes  more  than  2  times 
[9]. In yeast FACT assisted transcription of genes with 
highly  ordered  chromatin  structure  and  induced  genes, 
but  not  constantly  expressed  housekeeping  genes  [10]. 
This suggests that FACT may not belong to the category 
of  general  transcriptional  factors  and  may  be  required 
for only certain subtypes of transcription. Identification 
of a set of genes which requires FACT for transcription 
is hampered by the fact that cells in vitro are not viable 
upon knockdown of FACT [1]. Therefore as a first step 
table 1: Expression of FAct subunits in different organs of mouse and human
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lymphocytes ++ ++
large 
intestine
bottom crypt 
cells +++ +++
macrophages/ 
monocytes +++ +++
surface 
epithelial 
cells
- -
granulocytes - NA stroma - -
reticulocytes - NA
lung
alveolar 
epithelia - -
spleen ++ ++
air ducts 
epithelia +/- -
bone marrow +++ NA stroma - -
MALT ++ NA
mammary 
gland
epithelia + -
thymus +++ NA
adipose 
cells + -
liver
hepatocytes - -
nervous 
system
grey matter 
neurons +/- +/-
stroma - - white matter + +
kidney
nephrons - - glia - -
proximal 
tubular 
epithelia
-/+ -/+
Purkinje 
cells ++ NA
distal tubular 
epithelia -/+ - granule cells -
stroma - -
peripheral 
neurons - NA
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acinar cells - -
different 
organs
endothelial 
cells - -
ductal cells +/- - fibroblasts - -
Langerhans 
islets ++ - muscles - -
stroma - -
adipocytes - -
ovary
See details 
in the  text +++ +++
stomach
bottom crypt 
cells +++ +++ testes
See details 
in the   text +++ +++
surface 
epithelial cells - - endometrium
See details 
in the  text +++ +++
stroma - -
prostate
basal cells +/- +/-
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Figure 1. Expression of FACT subunits in hematological organs Immunohistochemical staining with antibodies against SSRP1, SPT16 
and Ki67 (except bone marrow) of   A. - bone marrow; B. –lymph node, C.- MALT; D. – spleen.  Areas in squares are enlarged below 
each image.  
to approach FACT dependent transcriptional program we 
seek to identify conditions which may require high level 
of FACT expression in cells.
 We did this through the analysis of FACT subunits 
expression in different mammalian (mouse and human) 
tissues and cells under different conditions to better 
understand  the  physiological  role(s)  of  FACT  and  the 
potential  implications  of  its  targeting  by  anticancer 
therapeutics. Our approach was based on the presumption 
that conditions associated with high FACT levels would 
be more likely to be dependent on FACT function than 
conditions  with  low  or  absent  FACT  expression.  The 
same assumptions can be applied to cell types and tissues 
differing in FACT expression levels.
Two methods were used to map FACT subunit 
expression  in  mammals.  First,  immunohistochemical 
(IHC) staining of normal human and mouse tissue sections 
was performed using antibodies against SSRP1 (human 
and  mouse)  and  SPT16  (mouse  only).  This  analysis 
demonstrated  that  FACT  subunits  are  not  ubiquitously 
expressed. On the contrary, FACT was expressed at very 
low or undetectable levels in most adult tissues with a 
few exceptions. The second method took advantage of 
the  wealth  of  mRNA  expression  data  available  in  the 
NCBI  Gene  Expression  Omnibus  (GEO)  database. We 
analyzed all available datasets in which either SSRP1 or 
SPT16 was measured in mammalian cells or tissues. This 
demonstrated that high or low FACT subunit expression 
is  not  stochastically  distributed  among  different 
experiments,  but  is  associated  with  certain  conditions. 
Western blotting and immunofluorescence were used to 
confirm the findings of this data mining. Overall, the two 
strategies for FACT expression analysis were concordant 
and demonstrated association of “high” FACT expression 
with the condition of “stemness” or undifferentiated states 
such as embryonic stem cells, germ cells, and progenitors 
of different types of cells. Accordingly, FACT levels were 
lower in more differentiated states. All of the observed 
“high-FACT” cell states/conditions are characterized by 
the  ability  of  cells  to  renew  themselves.  However,  we 
used staining of Ki67 proliferation marker as well as in 
vitro systems for experimental modulation of proliferation 
and differentiation to show that FACT expression is not 
directly associated with the proliferative status of cells or 
tissues. 
rEsults
Expression of FAct subunits in normal 
mammalian tissues is not ubiquitous
Expression  of  the  SSRP1  and  SPT16  subunits  of 
FACT was studied by immunohistochemistry in normal 
tissues of adult mice (FVB, 8-12 weeks old, male and 
female) and humans (control non-cancerous tissues 
from cancer patient on tumor tissue microarrays (TMA) 
provided  by  RPCI  Pathology  Network  Recourse).  A 
summary of the results is presented in Table 1. In general, 
Figure 1: Expression of FAct subunits in hematological and lymphoid organs. Immunohistochemical staining with antibodies 
against SSRP1, SPT16 and Ki67 (except bone marrow) of A. - bone marrow; B. –lymph node, C.- MALT; D. – spleen.  Areas in squares 
are enlarged below each image. Oncotarget 4 www.impactjournals.com/oncotarget
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the pattern of SSRP1 and SPT16 expression was similar 
between mouse and human tissues of both genders. We 
also  observed  strong  similarity  in  the  distribution  of 
SSRP1 and SPT16 staining on most of the slides. This 
suggests that the two FACT subunits are expressed in a 
coordinated manner, which is consistent with their known 
function as a heterodimeric complex and with a previously 
reported study in plants [8]. 
The majority of adult human and mouse tissues did 
not stain positively for either FACT subunit (Table 1 and 
Fig.S1). However, high levels of SSRP1 and SPT16 were 
observed  in  some  cells  of  the  bone  marrow  (Fig.1A), 
and  thymus;  in  lymph  nodes  (with  the  highest  levels 
observed in germ centers of lymphoid follicles; Fig.1B), 
and among lymphocytes of mucosa-associated lymphoid 
tissue (MALT; Fig.1C). Both SSRP1/SPT16-positive and 
-negative cells were detected in the spleen with more or 
less even distribution between the red and white pulp (Fig. 
1D). 
One of the cell types showing the strongest FACT 
subunit staining were the epithelial cells at the bottom of 
crypts in all parts of the intestine and in the stomach, with 
staining gradually decreasing up to the top of crypt (Fig.2). 
Epithelial cells of villi and stromal cells of the intestine 
were negative for FACT expression as were stromal cells 
of all other organs tested (Fig. 1-4, S1 and Table 1). 
Many SSRP1/SPT16-positive cells were observed in 
ovary and uterus. However, we were not able to reliably 
interpret the data for SPT16 due to strong cytoplasmic 
background staining. Therefore, we only describe SSRP1 
distribution in these organs. The cells of the mouse ovary 
(no  full  size  human  ovary  were  stained)  showing  the 
strongest  SSRP1  staining  were  follicle  cells.  Oocytes 
were  also  positive.  It  appeared  that  transformation  of 
a  follicle  into  a  corpus  luteum  was  accompanied  by  a 
decline in SSRP1 expression. Within an ovary, there was 
a gradient of SSRP1 staining between different corpi with 
levels ranging from equal to that seen in follicle cells to 
nearly SSRP1-negative (Fig. 3A, compare corpi I, II, III 
and IV). Ovarian medulla cells were less SSRP1-positive 
and in some cases were nearly SSRP1-negative. Stromal 
cells were negative. The distribution of SSRP1-positive 
cells  with  ovarian  tissue  suggests  that  that  there  is  a 
cycle of SSRP1 expression in the mouse ovary, probably 
coinciding with the developmental cycle of ovarian cells. 
Endometrial cells of the uterus and epithelial cells 
of the fallopian tubes were found to be strongly SSRP1-
positive, with the most intense staining observed among 
fimbriae cells of the infundibulum  (Fig.3B,  C).  Both 
SSRP1-positive  and  -negative  cells  were  seen  in  the 
myometrium (Fig.4C).
Differential expression of SSRP1/SPT16 was also 
Figure 2: Expression of FAct and proliferation marker Ki67 in intestine. Immunohistochemical staining of a section of small 
intestine with antibodies against SSRP1, SPT16 and Ki67. Blue arrows show Ki67 negative cells at the bottom of a crypt.Oncotarget 5 www.impactjournals.com/oncotarget
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observed within testes, with spermatogonia cells being 
the  most  positive,  spermatocytes  showing  less  intense 
staining, and supporting cells (Leydig and Sertoli cells) 
and stroma being negative (Fig. 4A). As in the ovary, 
this pattern is suggestive of FACT expression changing 
in  association  with  the  developmental  cycle  of  male 
reproductive cells.
Most  of  the  cells  in  the  liver  and  pancreas  were 
SSRP1/SPT16-negative, although there were some weakly 
positive cells among Langerhans islets (Fig. S1a,d and 
c,f). Among other endocrine tissues, the cells of the zona 
glomerulosa in the adrenal cortex were found to express 
SSRP1 (Fig.S1i,l). These cells produce mineralcorticoids. 
Other cells of the adrenal cortex, as well as cells of the 
adrenal  medulla,  did  not  show  detectable  SSRP1  or 
SPT16 staining. Lung epithelial and stromal cells were 
negative (Fig.S1 b,e). Some kidney tubular epithelial cells 
were moderately positive, with the frequency of positivity 
increasing  in  more  distal  regions  (Fig.S1g,j).  SSRP1/
SPT16-positive  cells  were  also  observed  among  brain 
neurons, such as Purkinje cells of the cerebellum (Fig. 
S1h,k), although the CNS was not analyzed in detail.
Taken together these data indicate that FACT 
subunits are not ubiquitously expressed at high levels in 
any  mammalian  tissue.  Even  in  those  tissues  showing 
the  highest  frequency  and  intensity  of  FACT  staining 
(primarily  lymphoid  and  reproductive  organs),  a 
significant number of negative cells were also observed. 
Expression of FAct subunits and the Ki67 
proliferation marker are not correlated
The mosaic distribution of FACT expression in 
lymphoid and some other organs suggested that it might 
be related to the proliferation status of cells. Although 
this hypothesis clearly could not be true for all tissues 
(e.g., FACT-positive Purkinje cells in cerebellum do not 
proliferate), we tested it by comparing serial mouse tissue 
sections  stained  for  Ki67  antigen  (a  well-established 
marker of proliferation) and FACT subunits. 
There was no substantial similarity between FACT 
and  Ki67  expression  in  any  of  the  hematological  and 
lymphoid organs assessed. For example, nearly all cells in 
Figure 3: Expression of FAct in reproductive organs. A-C. Immunohistochemical staining of a section of ovary (A), infundibulum 
of fallopian tube (B), uterus (C) with antibodies against SSRP1and Ki67. D. Immunohistochemical staining of a section of testes with 
antibodies against SSRP1and SPT16. Note the orderly maturation of germ cells from the base to the center of the lumen.  E. Higher 
magnification of a portion of lumen in testes stained with anti-SSRP1 antibody. Spermatogonia (I, along the basement membrane), primary   
(II) & secondary (III) spermatocytes, spermatids, (IV)  and spermatozoa  (SZ) are shown. SM – smooth muscle cells, LC – Leydig cells, 
SC – Sertoli cells. Oncotarget 6 www.impactjournals.com/oncotarget
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lymph node follicles and MALT were FACT-positive, but 
only a limited number were Ki67-positive (Fig. 1B, C). 
Moreover, the strongest FACT staining in these structures 
did not coincide with Ki67 positivity, although co-staining 
of the same slide is needed to make a final conclusion. In 
the spleen, there was not a substantial difference in FACT 
expression  between  the  red  and  white  pulp;  however, 
the frequency of strongly  Ki67 positive cells was much 
greater in the red pulp than in the white pulp (Fig. 1D). 
The  highest  coincidence  of  SSRP1  and  Ki67 
positivity was seen in the intestinal epithelium (Fig.2). 
Intestinal stem cells and highly proliferative progenitor 
cells  reside  at  the  bottom  of  intestinal  crypts  and  the 
proliferation potential of the cells decreases as they move 
towards  the  top  of  a  crypt.  This  was  reflected  by  the 
pattern of Ki67 staining. Importantly, the cells at the very 
Figure 4: Identification of conditions associated with changes in FACT subunit expression through analysis of the 
GEo database.  Experimental conditions associated with either SSRP1 or SPT16 expression level changes were selected and ranked 
based on (i) the proportion of all experiments testing similar conditions in which the level of mRNA for either FACT subunit was changed 
(proportion of all experiments), (ii) the maximal level of change (maximal change), and (iii) the average level of change (average change). 
Cut-off lines for SSRP1 and SPT16 in corresponding colors were drawn using parameters generated for experiments where knockout or 
knockdown tissues or cells were used (technical classification). In the left upper corner of each plot, the Pearson correlation coefficient 
between changes in SSRP1 and SPT16 expression levels is shown. Oncotarget 7 www.impactjournals.com/oncotarget
bottom of a crypt are actual intestinal stem cells, which 
proliferate more slowly than epithelial progenitors located 
2-3 cells higher up in the crypt (Fig.3). This explains the 
observation of one or two Ki67-negative cells at the bottom 
of many crypts. However, no similar FACT-negative cells 
were seen at the bottom of most crypts, again suggesting 
that although the pattern of FACT and Ki67 staining in all 
parts of the intestine is similar, it is not identical.
The ovary and uterus also showed similarity, but not 
identity, in distribution of FACT- and Ki67-positive cells. 
We observed a gradient of FACT positivity in ovaries with 
the highest expression seen in follicles and oocytes and 
the lowest expression seen in old corpi lutei and medulla 
cells.  In contrast, only cells of the inner mass of follicles 
were Ki67 positive. In the uterus, Ki67-positive cells were 
detected  only  in  the  endometrium,  while  many  FACT-
positive cells were present in the myometrium as well as 
the endometrium (Fig.3). 
Taken together, these data indicate that expression of 
FACT subunits is not directly related to the proliferative 
status of cells in the organs analyzed. 
ssrP1/sPt16 mrnAs and proteins are 
distributed in similar patterns in normal tissues
There are several microarray studies where SSRP1/
SPT16  mRNA  expression  was  compared  between 
different  normal  human  and  mouse  tissues  (Table  S1). 
First  what  we  noticed  that  mRNA  of  both  subunits  in 
contrast to proteins were easily detectable and expressed 
at quite substantial level in almost all adult tissues tested. 
There  was  less  variability  in  expression  of  SSRP1/
SPT16 mRNAs between different adult tissues than we 
Table 2: Classification of studies which demonstrated differential level of FACT subunits between experimental 
conditions
Category Keyw ords
Studies measuring SSRP1 level Studies measuring SPT16 level
number of 
similar 
studies 
(datasets)
number of 
studies 
showing 
change in 
SSRP1 level 
%
maximal 
change
average
number of 
similar 
studies 
(datasets)
number of 
studies 
showing 
change in 
SPT16 level 
%
maximal 
change
average
embryonic 
development
embryo, 
prenatal 11 9 81.82% 9.3 2.62 9 6 66.67% 5.44 2.39
IFNgamma IFNgamma 9 6 66.67% 2.1 1.33 7 3 42.86% 1.4 1.1
HDA C inhibitors HDAC 8 5 62.50% 2.3 1.31 6 3 50.00% 1.9 1.3
stem cells and 
differentiation
stem, precursor, 
progenitor, 
differentiation
63 51 80.95% 8.56 2.39 46 35 76.09% 3.57 1.89
proliferative 
activity
proferation, 
division, growth 31 16 51.61% 3.69 1.50 28 13 46.43% 2.69 1.34
inflammatory or 
immunological 
disorders 
diseases
manual search 17 7 41.18% 2.3 1.29 15 6 40.00% 2.4 1.3
oncogenes 
activity
manual search 14 7 50.00% 5.1 1.85 11 8 72.73% 4.4 1.9
DNA  
demythelation
agents
demythelation 4 1 25.00% 1.5 1.13 2 1 50.00% 1.4 1.1
LPS LPS 25 6 24.00% 2 1.16 19 6 31.58% 1.9 1.1
infections infection 51 9 17.65% 2.8 1.16 32 6 18.75% 2.2 1.18
DNA  damage manual search 8 1 12.50% 2.1 1.14 5 1 20.00% 1.7 1.14
age age 27 2 7.41% 2.3 1.11 22 1 4.55% 1.8 1.036364
all experiments NA 3686 387 10.50% NA 1 2418 6 0.25% 1
KO and KD 
experiments
NA 131 23 17.56% 1.82 1.15 99 8 8.08% 1.9 1.08Oncotarget 8 www.impactjournals.com/oncotarget
observed for SSRP1/SPT16 proteins (maximal difference 
for mRNAs was < 3-fold). As in our IHC analyses, we 
observed  that  expression  levels  of  SSRP1  and  SPT16 
mRNAs were generally concordant, although there were 
some  discrepancies  (e.g.,  study  GDS565  showed  high 
expression of SPT16, but not SSRP1, in the hypothalamus, 
Table S1). 
Organs in which expression of SSRP1 was higher 
than in other tissues (2 times higher than mean of all tissues 
in a study) in most of the analyzed studies (both human 
and mouse) were testis and ovary, followed by thymus and 
uterus. In mouse, higher than average expression of SSRP1 
was also observed in spleen and mammary gland. Tissues 
in which high expression of SSRP1 mRNA was observed 
in at least one study were bone marrow and trachea (both 
species), placenta, bladder, and tonsils (human only), and 
lymph node, bone, and umbilical cord (mouse only).
Like  SSRP1,  SPT16  mRNA  was  most  frequently 
detected at higher than average levels in testis and ovary. 
In  addition,  single  studies  showed  elevated  SPT16 
expression in human thymus, mammary gland, skeletal 
muscle, heart and peripheral blood lymphocytes and in 
mouse spleen and hypothalamus. 
Overall,  the  data  from  these  previously  reported 
studies  show  that,  for  both  mouse  and  human,  SSRP1 
and  SPT16  mRNA  expression  is  highest  in  tissues  of 
hematological and reproductive systems. This is consistent 
with the patterns of SSRP1 and SPT16 protein abundance 
that we observed via IHC staining (see above).
Identification  of  conditions  associated  with 
changes in FAct expression
Existing mRNA expression data was not only useful 
for examining the tissue distribution of FACT expression 
(see  above),  but  also  allowed  us  to  identify  specific 
conditions associated with altered FACT expression. We 
accomplished this by analyzing mRNA expression data for 
both FACT subunits from a large number of independent 
studies  available  at  NCBI  Gene  Expression  Omnibus 
(GEO) site [11, 12]. To facilitate data interpretation, we 
limited  our  analysis  to  mammalian  species.  We  found 
a total of 3686 entries for SSRP1 and 2418 entries for 
SPT16 (roughly 2000 experiments in which expression of 
at least one subunit was measured). The number of entries 
for  SSRP1/SPT16  in  different  species  was  as  follows: 
1462/1106  –  H. sapiens,  1746/1140  –  M. musculus, 
269/191 – R. norvegicus, 13/6 – M. mulata, 16/16 – C. 
lupus, 2/2 – B. taurus. This approach was expected to 
provide  unbiased  detection  of  physiological  roles  of 
FACT since the analyzed studies were generally global 
gene expression profiling studies that tested a wide array 
of different conditions without specific focus on FACT. 
Although  there  are  several  software  programs 
available  for  analysis  of  multiple  sets  of  microarray 
data,  most  are  designed  to  compare  healthy  versus 
diseased conditions (e.g., Oncomine) and those that are 
capable  of  analyzing  changes  in  expression  between 
other conditions were not satisfactory due to the limited 
accuracy  of  the  classification  of  conditions  that  they 
provide. Therefore, we performed a “manual” analysis of 
the GEO database using the GEO Profiles search engine 
(see Materials and Methods for details). Briefly, we first 
selected all experiments in which expression of either 
SSRP1 or SPT16 was different between any conditions 
(for  criteria  see  Material  and  Methods).  We  then 
classified all conditions in which expression of SSRP1/
SPT16 was changed according to the biological process 
involved (see Table 2), such as embryonic development, 
differentiation, treatment with a certain compound, etc. 
We then performed another GEO Profiles search using 
combinations of SSRP1/SPT16 (or Supt16h, official name 
of gene) and keywords describing biological processes 
used for classification (embryo, stem cell, differentiation, 
compound name etc). This process revealed the proportion 
of  experiments  in  which  expression  of  SSRP1/SPT16 
was changed in similar conditions from all experiments 
testing the same conditions. For example, out of a total 
of 25 experiments in which SSRP1 gene expression was 
compared  between  LPS-stimulated  and  control  cells,  a 
change in SSRP1 expression level after LPS stimulation 
was  observed  in  6  experiments  and  no  change  was 
observed in 19 experiments.
Through this process, we identified (i) conditions in 
which FACT levels were changed most frequently (based 
on the proportion of experiments showing a change in 
FACT expression out of all experiments with similar 
conditions); (ii) conditions associated with the maximal 
change in FACT levels; and (iii) the average change in 
FACT levels in experiments with similar conditions. All 
experimental conditions associated with altered FACT 
expression were ranked according to these parameters. To 
establish a cut-off line to distinguish conditions in which 
FACT levels were changed with higher than background 
frequency,  we  used  two  approaches:  (i)  we  calculated 
the same parameters (except maximal change) for all 
experiments  that  measured  FACT  levels;  and  (ii)  we 
calculated the same three parameters for a list of mRNA 
expression experiments classified according to technical 
rather than biological principles (i.e., experiments with 
knockout or knockdown of any gene). We used the highest 
number generated by either approach as the cut-off for 
each parameter.
Based  on  all  three  parameters,  two  conditions, 
“embryonic  development”  and  “stem  cells  and 
differentiation”,  were  most  clearly  associated  with 
changes in FACT expression level (Fig.4). We identified 
other conditions in which all three parameters were 
higher  than  the  cut-off  (e.g.,  “proliferative  activity“ 
and  “expression  of  oncogenes”),  but  they  were  much 
more weakly associated with FACT expression than the Oncotarget 9 www.impactjournals.com/oncotarget
GEO 
Dataset 
Study
Tissue 
Compared
Species
SSRP1 SPT16 (=Supt16h)
description of 
change
fold 
change
p-value
description 
of change
fold 
change
p-value
GDS2577 liver  M. musculus higher in embryo 
versus adult 9.30 3.6233E-39
higher in 
embryo versus 
adult
5.44 1.8437E-26
GDS1511 whole embryos M. musculus higher at E8.5 
than  at  E12  2.62 0.026863
higher at E8.5 
than  at  E12  3.29 0.038166
GDS813
preimplantation
embryos M. musculus highest in 
blastocyst  2.44 4.7105E-08
no change 
between oocyte 
and blastocyt
1.00 -
GDS2283 brain M. musculus
higher in embryo 
at E13.5 than in 
newborn
2.16 0.000113
higher in 
embryo at 
E13.5 than in 
newborn(not 
statistically 
significant
1.37 0.059308
GDS782 lungs  M. musculus higher at at E18.5 
than at birth  2.14 0.02756044 No data
GDS827 heart M. musculus decrease from 
E10.5 to E18.5  2.08 <0.000001
decrease from 
E.10.5 to E18.5 1.41 0.000046
GDS3442 brain M. musculus higher at E9.5 
than at E13.5 1.69 <0.000001
higher at E9.5 
than at E13.5
inconsistent 
data -
GDS3641 yolk sac M. musculus higher at E9 than 
at E10.5 1.53 2.787E-05
higher at E9 
than at E10.5 1.84 0.000056
GDS1724
gonadal somatic 
cells from male 
and female 
embryos
M. musculus
higher  at E10.5 
than at E11.5 in 
males
1.26 0.000001 No difference - -
GDS739
fetal orofacial
tissue M. musculus
no change 
between E12-
E14 (unrealible 
data)
1 - No data
GDS1003
bovine early 
embryo B. Taurus
no clear change 
big variability  (one 
panel)
- -
no clear 
change big 
variability (one 
panel)
- -
first  two  conditions  (Fig.5).  There  were  high  positive 
correlation between changes in SSRP1 and SPT16 level 
for all conditions (κ>0.85).
FAct is expressed at different levels in 
differentiated and non-differentiated cells  
Having  identified  conditions  associated  with 
changes in FACT expression, the next step was to 
determine whether the change in FACT level in a given 
condition was in the same or opposite direction (increase 
or decrease) in different experiments (the initial selection 
did  not  distinguish  the  direction  of  the  change).  Our 
findings for the categories of “embryonic development”, 
“stem cells and differentiation”, “proliferative activity“, 
and “expression of oncogenes” are described below.
Table  3  summarizes  all  of  the  experiments  in 
which  FACT  levels  were  measured  at  different  stages 
of embryonic development. In all cases except for one, 
when SSRP1 levels showed a change, it was lower at later 
stages of embryonic or post-embryonic development than 
at earlier stages (Fig.S2B-C). The single case in which this 
was not observed was in pre-implantation embryos. In this 
case, SSRP1 expression was low in zygote and elevated 
towards the blastocyst (Fig.S2A). Changes of SPT16 were 
similar except that expression of SPT16 was not increased 
in the blastocyst as compared with earlier stages of pre-
implantation embryos (Table 3). Therefore, this analysis 
of  data  from  multiple  microarray  experiments  using 
different tissues indicates that FACT expression increases 
during development of the pre-implantation embryo up to 
at least the blastocyst stage and then declines during the 
course of embryonic development.   
Table S2 summarizes experiments in which FACT 
expression was compared in cells at different stages of 
differentiation.  In  45  out  of  51  (88%)  SSRP1  studies 
and in 33 out of 35 (94%) SPT16 studies, expression of 
FACT subunits were lower in more differentiated cells 
than in stem cells, progenitor cells and less differentiated 
table  3: summary of studies measured levels of FAct subunits in embryonic tissuesOncotarget 10 www.impactjournals.com/oncotarget
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cells (Fig.S3). FACT expression declined after induction 
of  differentiation  (Fig.  S3A,  C-F)  and  increased  after 
induction  of  regeneration  (Fig.S3B).  Very  few  studies 
showed  increased  expression  of  SSRP1  (6  out  of  51, 
12%) or SPT16 (2 out of 35, 6%) in differentiated cells as 
compared to progenitor cells (Table S2, entries highlighted 
in red). 
It  is  difficult  to  completely  separate  in  vitro 
conditions that induce differentiation from those that 
cause pure growth arrest. Therefore, we excluded from 
our  “proliferation  activity”  group  all  studies  where 
“differentiation”  was  mentioned  (Table  S3).  Although 
this is not ideal approach it allowed formal separation 
of  these  two  phenomena  for  the  analysis.    SSRP1/
SPT16  expression  was  changed  in  52%/46%  of  the 
remaining “proliferation-specific” experiments in which 
cells  of  different  proliferative  status  were  compared, 
respectively.  The  majority  of  studies  (88%/69%)  that 
showed  a  proliferation-associated  change  in  SSRP1/
SPT16 expression showed a decrease in SSRP1/SPT16 
in conditions of growth arrest or an increase in SSRP1/
SPT16 in conditions of active proliferation (Tables 2 and 
S3). From this analysis we concluded that although there 
association of high FACT and proliferation and low FACT 
and quiescence this association was seen only in less than 
half of studies (i.e. SSRP1 higher in proliferating cells 
than in arrested in 49% of studies (88 % of 56% of total 
studies measuring proliferation) and SPT16 in 32% (69% 
of 46% of total studies). Therefore, similar to our IHC 
experiments,  this  analysis  allowed  us  to  conclude  that 
changes in proliferative status are not strictly associated 
with changes in FACT expression. 
Finally, we analyzed how the activity of oncogenes 
influences  FACT  expression  levels.  In  71%/69%  of 
experiments in which oncogene activity was induced in 
different cells in vitro or in vivo, SSRP1/SPT16 levels 
were  increased  (Table  S4).  In  contrast  to  induction  of 
proliferation, there were no examples of reduction of 
FACT  level  in  cells  with  elevated  oncogene  activity. 
Among the oncogenes assessed in the available studies 
were N-myc, mutated RAS or activated MEK, Gli1 and 
Smoothed, SV40. 
Other  experimental  conditions  associated  with 
less prominent changes in FACT expression included 
treatment  with  LPS,  IFNγ,  or  HDAC  inhibitors  and 
DNA  demethylation  or  damage  (Table  2  and  Fig.  4). 
Determination of the significance of these associations 
will require additional investigation.
FAct subunit expression levels are changed upon 
experimental induction of differentiation, but not 
proliferation
The RNA expression and IHC data described above 
Figure 5: FAct level is changed upon differentiation 
and  transformation,  but  not  with  a  change  in  the 
proliferation status of cells. A. C2C12 myoblast cells were 
grown to confluency in regular growth medium. At time 0, when 
cells were confluent, the medium was changed to differentiation 
medium. Cell samples were collected on the indicated days before 
and after induction of differentiation and the level of SSRP1, 
SPT16,  myosin  heavy  chain  (MHC1,  differentiation  marker) 
were assessed using western blotting. β-actin was assessed as a 
loading control.  B. HT1080 fibrosarcoma cells were grown to 
confluency and then placed into low serum medium (0.5% FBS) 
to induce G1 arrest.  Forty-eight hours later, SSRP1 and SPT16 
proteins were detected by Western blotting and DNA content 
was  measured  by  FACS  analysis  of  fixed  propidium  iodide- 
stained cells.  C. Effect of induced expression of CDK inhibitor 
p21/Waf1 on the level of FACT subunits. Western blotting of 
HT1080  cells  with  IPTG-regulated  expression  of  p21/Waf1 
collected at different time points after addition of IPTG. Oncotarget 11 www.impactjournals.com/oncotarget
suggested that FACT expression levels are related to the 
differentiation status of cells. To directly test whether FACT 
expression changes during the process of differentiation, 
we evaluated FACT protein levels in an in vitro system 
in  which  cultures  of  C2C12  myoblasts  are  induced  to 
differentiate into myotubes by growth in a special medium 
(“differentiation medium”). Reduction of FACT mRNA 
levels upon differentiation in this model was previously 
demonstrated  in  several  microarray  hybridization 
experiments  (Fig.  S3C)  and  another  study  showed 
reduction of SSRP1 protein level but did not assess SPT16 
[7]. This model also had the potential to reveal whether 
FACT levels change as a result of decreased proliferation 
or induced differentiation, since before addition of 
differentiation medium, the cell cultures are grown to 
high density and the cells become growth arrested due to 
contact inhibition [13]. We did not observe any change in 
FACT protein levels (either subunit) during the period of 
culture growth before addition of differentiation medium 
(days -2-0). In contrast, after addition of differentiation 
medium on day 0, there was a clear gradual decrease in 
SSRP1 and a sharp reduction in  SPT16 protein levels 
in  parallel  with  increased  expression  of  myosin  heavy 
chain, a marker of C2C12 differentiation (Fig. 5A). These 
results provide additional support for our conclusion that 
FACT expression is related to differentiation status, not 
proliferation status.
We further tested whether FACT levels are associated 
with changes in the proliferative status of cells by using 
several independent methods to arrest the growth of human 
fibrosarcoma HT1080 cells (i.e.,  growth to high density/
contact inhibition, incubation of cells in medium with low 
serum  or ectopic expression of the CDK inhibitor, p21/
Waf1). No changes in SSRP1 or SPT16 expression were 
observed under any of these conditions (Fig. 5B, C), again 
providing support for a lack of direct association between 
proliferation and FACT expression.
Overall,  these  experiments  with  cultured  cells 
provided confirmation  on the protein level of tendencies 
that we observed on the mRNA level in our analysis of 
publically  available  microarray  data,  and,  therefore, 
validated our approach.
dIscussIon
Known roles of FACT include facilitating 
transcription from nucleosomal templates, DNA damage 
responses, and V-D-J recombination [3, 4, 14].  Many 
mechanistic  details  of  FACT’s  involvement  in  these 
processes have been uncovered (for review see [15, 16]. 
For  example,  it  is  well-established  that  FACT  plays  a 
unique role in regulating assembly of nucleosomes and 
exchange of some types of H2 histones.  These activities 
influence  transcription  and  DNA  damage  responses.   
However,  absence  of  FACT  subunits  does  not  have 
a  general  inhibitory  effect  on  transcription,  but  only 
interferes with expression of a subset of genes [8-10].  It 
has been postulated that those transcriptional programs 
that are FACT-dependent are likely tightly regulated, non-
housekeeping programs and that remodeling of chromatin 
by FACT provides one level of their control.  For example, 
we  showed  that  transcription  by  the  stress-responsive 
transcription factor NF-κB requires FACT activity [1].  
In large part, the cell type- and tissue-specificity of 
FACT function has not been previously explored.  The 
functional consequences of FACT inhibition in different 
types of cells were not studied. Moreover, most FACT 
studies were run in yeast or human tumor cells in which 
FACT  subunits  are  abundantly  expressed.    A  limited 
number of studies showed that some differentiated cells 
express  little  or  no  FACT    [7],  [8].  These  studies,  as 
well as reports implicating FACT in replication [2, 17], 
recombination [18] and mitosis [19], suggest that FACT 
expression levels may be associated with the proliferative 
status of cells. However, we observed that although mouse 
and human diploid fibroblasts actively proliferate in vitro, 
they have very low or nearly undetectable levels of FACT 
[1]. 
Due  to  our  discovery  that  candidate  anti-cancer 
compounds  Curaxins  cause  functional  inactivation 
of  FACT  [1],  we  were  interested  in  gaining  a  better 
understanding of the role(s) of FACT in the context of 
mammalian  organisms.    Since  FACT  function  requires 
that it is expressed, we performed a detailed investigation 
of FACT expression in different organs and tissues of 
mice and humans as a first step toward identification of 
FACT’s biological roles.  We found that expression of 
the two subunits of FACT is highly correlated on both 
the RNA and protein levels, consistent with their activity 
as  a  complex.  Some  discrepancies  were  observed  on 
the RNA level, which may explain the results of study 
showing that inactivation SSRP1 or SPT16 in tumor cells 
affected  expression  of  slightly  different  sets  of  genes 
[9]. RNA levels of both FACT subunits were much less 
variable than protein levels.  This may be a reflection of 
different sensitivities of the detection methods used and/
or differences in the population of cells analyzed by each 
method (individual cells in IHC versus a pooled population 
in most RNA expression profiling studies). Alternatively, 
this may indicate regulation of FACT subunit abundance 
on the level of translation or protein stability, rather than 
(or in addition to) on the level of gene expression. In 
addition, conclusions about RNA levels were made based 
on  analysis  of  multiple  independent  studies  run  under 
different  conditions,  which  to  some  extent  adds  value 
to  these  observations.  However,  substantially  different 
results coming from different experiments cannot just be 
averaged and may require investigation of the material 
and methods used in each study, which was not taken into 
account in our study. 
FACT protein levels were variable between tissues 
and mosaic in those organs where FACT expression was Oncotarget 12 www.impactjournals.com/oncotarget
detected. Most adult tissues did not have detectable levels 
of either FACT subunits. Positive cells were found in organs 
in which presence of proliferating or undifferentiated cells 
was expected with some exceptions such as neurons in 
brain or Langerhans islets in pancreas. The function of 
FACT in these cells remains to be investigated.
Hematopoietic  (including  lymphoid)  and 
reproductive organs and crypts of intestine were the organs 
found to have the highest proportion of FACT-positive 
cells and one of the highest level of proliferative cells 
among adult tissues. The first two types of organs also 
showed the highest levels of FACT mRNA expression, 
while intestine was not FACT-positive in human or mouse 
mRNA expression studies. This may be due to the low 
proportion of FACT-positive cells among other cells in the 
intestine. 
Mosaic expression of FACT among cells of the same 
type suggests that it may be associated with a particular 
cellular  state.  Analysis  of  in  vivo  distribution  of  the 
proliferative marker Ki67 and in vitro manipulations of 
cell proliferation demonstrated that FACT expression is 
not directly associated with the proliferative activity of 
cells.  In addition, FACT levels were not changed during 
cell cycle transit [7].  A second potential explanation for 
the observed mosaic expression of FACT is its association 
with a certain stage of cell differentiation.  Our finding of 
FACT expression specifically in the cells at the very bottom 
of intestinal crypts, but not those higher up in the crypt 
suggests that FACT may be expressed in undifferentiated 
progenitor cells or stem cells. This hypothesis is well in 
line  with  the  expression  profiling  data  for  both  FACT 
subunits:  high  expression  levels  were  most  frequently 
observed  in  different  embryonic  cells  and  fetal  tissues 
and FACT mRNA levels were almost always higher in 
stem and progenitor cells as compared to differentiated 
cells. Moreover, this hypothesis was confirmed directly 
by  our  demonstration  that  induction  of  mouse  C2C12 
myoblast  differentiation  in  vitro  was  accompanied  by 
a  sharp  reduction  in  SPT16  and  a  gradual  decrease  in 
SSRP1 levels (Fig.5A). Importantly, the protocol for in 
vitro differentiation of C2C12 cells requires growth of 
the cells to high density before addition of differentiation 
medium.  Cells  at  this  density  undergo  growth  arrest 
due to contact inhibition, which allowed us to measure 
FACT levels in growth arrested undifferentiated cells as 
compared to differentiated cells.  FACT levels remained 
high  in  growth  arrested  cells  and  only  dropped  after 
induction of differentiation, thus confirming association 
of FACT expression with differentiation status rather than 
proliferative status. 
Therefore, three types of data, distribution of FACT 
proteins in cells of different organs, expression profiles of 
FACT mRNAs in different experimental conditions, and 
direct experimental manipulations with cell differentiation 
and proliferation, all suggest that high FACT expression is 
a marker of undifferentiated, progenitor and stem cells and 
that low FACT expression is a marker of differentiated 
cells.    Accumulated  data  from  a  number  of  different 
studies has revealed a so called embryonic stem (ES) cell-
like  gene  expression  signature  [20].  SPT16  expression 
was already included in this signature based on finding 
of SPT16 among myc-responsive targets using microarray 
hybridization and myc binding to SPT16 promoter using 
ChIP-sequencing [20].  Our results confirm inclusion of 
SPT16 in an ES cell-like gene expression signature and 
indicate that SSRP1 should be included as well.  Future 
studies will be required to establish the functional 
role of FACT in stem/progenitor cells and its effect on 
differentiation and dedifferentiation.  
Association  of  FACT  with  ES  cell-like  signature 
explains potential role of FACT in cancer, as gene 
expression studies demonstrated presence of this signature 
in many cancers as well as other features of stem cells. 
From the other side, limited expression of FACT in adult 
differentiated cells and tissues suggests that FACT may 
be used as a target for temporal therapeutic inhibition in 
cancer treatment with limited harm to normal tissues. 
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mAtErIAl And mEthods
cells, constructs and chemicals
HT1080  cells  were  obtained  from  ATCC  and 
maintained  in  DMEM  supplemented  with  10%  heat 
inactivated (HI) FBS and antibiotics. HT1080-p21 cells 
were  obtained  from  Igor  Roninson  (Department  of 
Molecular Genetics, University of Illinois at Chicago) and 
were already described [21]. C2C12 skeletal myoblasts 
were obtained from Dr. Asoke Mal (Roswell Park Cancer 
Institute (RPCI), Buffalo, NY).  Cells were maintained in 
growth medium consisting of DMEM with 20% HI FBS 
and antibiotics. 
 To induce differentiation of C2C12 cells, cells were 
transferred to differentiation medium (DM) consisting of 
DMEM with 2% HI horse serum (Gibco) and 10µg/mL 
insulin [13].  The formation of differentiated myotubes 
was observed within 24h of transfer to DM.  Samples 
were collected for immunoblotting every 24h for 7d after 
transfer to DM. IPTG, propidium iodide and polybrene 
were  from  Sigma  Aldrich,  Inc.  Lipofectamine  2000 
Reagent was from Invitrogen. Lentivirus packaging and Oncotarget 13 www.impactjournals.com/oncotarget
transduction was done as previously described [22]. 
Immunoblotting
Cells  were  lysed  in  Cell  Culture  Lysis  Reagent 
(Promega)  and  loaded  on  precast  4-20%  gradient  gels 
(Bio-Rad).    Gels  were  blotted  onto  PVDF  membranes 
(Bio-Rad, Inc.) and probed with the following antibodies: 
SPT16, SSRP1 (both from Biolegend, Inc.), anti-myosin 
heavy chain (MF20, kindly provided by Dr. Asoke Mal, 
Roswell  Park  Cancer  Institute),  and  β-actin (Sigma-
Aldrich, Inc.) as a loading control. 
Immunohistochemical staining
Sections of paraffin-embedded tissues were cut at 5µm, 
placed on charged slides, and dried at 60°C for one hour.   
Slides were cooled to room temperature, deparaffinized 
in three changes of xylene, and rehydrated using graded 
alcohols.  Endogenous  peroxidase  was  quenched  with 
aqueous 3% H2O2. For antigen retrieval, slides were heated 
in citrate buffer (pH 6.0) in a microwave for 20 min , then 
cooled for 15 min and washed in PBS/T. Slides were then 
loaded onto a Dako Autostainer and blocked for 5 min 
with  serum-free  protein  block  (Dako).  Blocked  slides 
were then stained for 1 h with mouse monoclonal anti-
SSRP1 (Biolegend; used at 1.7 µg/ml on human sections), 
goat polyclonal anti-SSRP1 (Santa Cruz, Cat. #sc-5909; 
used at 0.2 µg/ml on mouse sections), or goat polyclonal 
anti-SPT16 (Santa-Cruz, Cat. #sc-5915; used at 0.2 µg/ml 
on human and mouse sections).  Isotype-matched control 
antibodies (1.7 µg/ml mouse IgG2b or 0.2 µg/ml goat 
IgG) were used on duplicate slides in place of the primary 
antibody  as  a  negative  control.  After  washing,  slides 
were  incubated  with  biotinylated  goat  anti-mouse  IgG 
(Jackson ImmunoResearch Laboratories, Inc.) or donkey 
anti-goat  IgG  (Jackson  ImmunoResearch  Laboratories, 
Inc.), followed by the Elite ABC Kit (Vectastain), and 
DAB chromagen (Dako). Slides were then counterstained 
with Hematoxylin, dehydrated, cleared and covered with 
coverslips. All slides were scanned using Aperio system 
(Aperio  Technologies,  Inc).  Images  were  made  using 
Image scope software (Aperio Technologies, Inc).
Animal experiments
All animal procedures were done according to a 
protocol approved by the RPCI IACUC. FVB mice were 
purchased from Taconic. Female and male 8 week-old 
animals were euthanized by CO2 inhalation. Immediately 
after sacrifice, organs were collected and fixed in 10% 
buffered formalin.  
Analysis of GEo datasets for FAct subunit 
mrnA expression 
The NCBI GEO Profiles search engine [11, 12] was 
used to obtain all data entries in the NCBI Gene Expression 
Omnibus (GEO) database containing mammalian SSRP1 
or  SPT16  (Supt16h)  gene  expression  analysis.  From 
these, we selected all entries in which expression of 
SSRP1 or SPT16 was changed. The criterion for selection 
at this stage was a change in FACT subunit expression of 
1.25-fold or more between any of the conditions within 
the experiment if the Student test p value was <0.05. If 
a p value was not available (no replicates), then a 2.0-
fold change in expression was required for selection. The 
conditions that were identified as associated with changed 
SSRP1  or  SPT16  expression  were  classified  according 
to  the  biological  process  involved  (see Table  2).  Only 
categories with 2 or more independent experiments were 
used for further analysis. 
The next step in our analysis involved identification 
of other experiments within each category of interest that 
measured SSRP1 or SPT16 expression, but did not show 
a change in expression allowing selection in the preceding 
step.  This was done by  performing GEO Profiles searches 
using  word  combinations  of  either  SSRP1  or  SPT16 
and keywords for the biological process(es) included in 
each category (see Table 2 for the lists of categories and 
keywords). For some categories it was difficult to generate 
a keyword list sufficient for identification of all potential 
experiments (e.g.,  “Oncogenes activity”). In these cases, 
all  mammalian  SSRP1/  SPT16  entries  were  searched 
manually to find similar experiments (e.g., including all 
potential oncogenes, even if the word oncogene was not 
used in the experiment description). 
Once all potential entries had been identified for all 
categories, we calculated (i) the percentage of experiments 
in a given category in which SSRP1 or SPT16 expression 
was changed; (ii) the maximal change in SSRP1 and/or 
SPT16 expression level within each category; and (iii) 
the average change in expression within each category 
(including all experiments in which FACT subunit mRNA 
levels were measured). 
To  identify  categories  in  which  FACT  subunit 
expression  was  changed  more  frequently  and/or 
more  significantly  than  the  “baseline”  observed  in 
all experiments, we selected data for two additional 
categories:  “all  experiments”  and  “experiments  with 
knockout (KO) or knockdown (KD) of any gene”.  In the 
first category, we included all entries in which expression 
of  SSRP1  or  SPT16  was  measured  in  mammalian 
samples.  In the second category, we included experiments 
in which keywords KO or KD were used. The proportion 
of  experiments  in  which  SSRP1  or  SPT16  expression 
levels  were  changed  within  these  two  categories,  as 
well as the average and maximal change (only for KO 
and KD experiment), was used to establish cut-off lines Oncotarget 14 www.impactjournals.com/oncotarget
to distinguish experiments in which FACT expression 
changed  with  higher  than  background  frequency  and/
or  extent.We  also  calculated  coefficient  of  correlation 
between change in SSRP1 level and SPT16 level for all 
three parameters (Pearson coefficient).
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